NAOC and Chinese Authorities Tackle Counterfeit Cigarette Paper Network

LOUISVILLE, Ky.--(BUSINESS WIRE)--Turning Point Brands, Inc. (NYSE:TPB), parent company of North Atlantic Operating Company (NAOC), the exclusive licensee of the iconic Zig-Zag® brand of cigarette papers in North America, today announced that police from the city of Yiwu in Zhejiang Province in China have commenced a coordinated set of actions in multiple Chinese cities targeting what appears to be the country’s biggest networks supplying counterfeit cigarette paper products to the United States.


Police have disclosed that investigations, raids and detentions have already taken place against manufacturing facilities, packaging suppliers and trading companies in Yiwu and other cities. The police have discovered that the counterfeiters have been copying virtually every major international cigarette paper brand, including the Zig-Zag brand for the United States.

The actions have been supported with information and other assistance from the Yiwu Tobacco Monopoly Bureau and the enforcement support team at Alibaba.

It is expected that the police investigations will be completed by mid-2018, after which prosecutions may be brought against the key individuals behind the network. It is also expected that information identifying those companies and individuals in the United States purchasing counterfeit cigarette papers will be supplied.

According to James Dobbins, Senior Vice President and General Counsel of NAOC:

North Atlantic Operating Company has a zero-tolerance policy with respect to counterfeiting of its products. The company’s brand protection team has investigated distributors of fake papers for several years, filing legal actions wherever possible in the United States. We anticipate taking actions against those in the United States who are identified and revealed in these investigations.

"The latest actions by the Chinese police clearly demonstrate the resolve of the Chinese government to address the problem at its roots.

"To date, we are informed that the Yiwu police have seized several hundred thousand booklets of counterfeit cigarette papers of many popular brands, packaging materials sufficient to produce millions of additional units, sophisticated production equipment, and extensive production and sales data.

"We have offered Chinese authorities any and all further assistance they may need to investigate the current counterfeiting network, as well as others that are understood to be operating in China.”

Mr. Dobbins additionally noted:

"The Company has devoted substantial resources to pursue investigations and enforcement actions throughout the United States, targeting internet sellers, bricks-and-mortar distributors and retailers. While this has increased administrative expense, we believe it has also increased our sales of Zig-Zag cigarette papers in the United States. We expect to continue these activities for the foreseeable future."

About NAOC and Turning Point Brands, Inc.

NAOC is an indirect, wholly-owned subsidiary of Turning Point Brands, Inc. NAOC is the exclusive licensee and distributor of Zig-Zag brand cigarette rolling papers and accessories, as well as nicotine vapor products, in the United States and Canada. It also is the owner of the Zig-Zag brand for cigars and make-your-own cigarette and cigar products. Louisville, Kentucky-based Turning Point Brands, Inc. (NYSE: TPB) is a leading U.S. provider of Other Tobacco Products. TPB, through its three focus brands, Stoker’s® in Smokeless Products, Zig-Zag® in Smoking Products, and the VaporBeast® distribution engine in NewGen Products, generates solid cash flow which it uses to finance acquisitions, increase brand support and strengthen its capital structure. TPB does not sell cigarettes. More information about the company is available at its corporate website, www.turningpointbrands.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release speaks only as of the date hereof. New risks and uncertainties come up from time to time, and it is impossible for TPB to predict these events or how they may affect it. TPB has no obligation, and does not intend, to update any forward-looking statements after the date hereof, except as required by federal securities laws. Factors that could cause these differences include, but are not limited to, (i) unexpected developments and difficulties in the investigations and anticipated prosecutions and (ii) the results of the investigations may differ from the results currently anticipated.


Contacts

Mozaic Investor Relations, Inc.
Terry McWilliams, president
502-774-9238
ir@tpbi.com

Dow and USA Luge Technical Partnership Delivers Advanced Sleds for PyeongChang 2018

Collaboration at the intersection of science and sport developed sleds for superior performance



MIDLAND, Mich.--(BUSINESS WIRE)--People watching the Olympic Winter Games PyeongChang 2018 this month witnessed the power of a collaboration between USA Luge and The Dow Chemical Company (“Dow”). The USA Luge team competed with Olympians from around the world using sleds designed by their engineers and Official Technical Partner, Dow. The two organizations have been working together since 2007 to combine science, engineering and technology for superior sled performance on the track.

Dow is applying the knowledge of physical sciences and state of the art engineering tools to develop an advanced luge sled. For example, Dow engineers gather insights into the track dynamics through a computer based model which helps to understand the interplay between various types of forces acting on the athlete and sled. Through its advanced manufacturing and testing capabilities, Dow creates prototypes of new designs and validates them with internal testing. Promising ideas are further tested on the track by USA Luge athletes who are able to assess the practical advantages of the changes.

By transforming the end-to-end process of sled R&D, design and manufacturing, Dow helps to continually innovate the sleds that the USA Luge team uses,” said Gordy Sheer, Director of Marketing and Sponsorship of USA Luge.

Exceptional solutions require exceptional teams and teamwork,” said Louis A. Vega, Dow’s vice president of Olympic & Sports Solutions. “Dow’s long history and deep expertise in materials science combined with our drive for innovation complements USA Luge’s drive for sporting excellence and breakthrough performances. Together, we have been able to help push the limits of design possibilities which in turn has given Dow new insights for our broad portfolio of solutions. We are proud of this partnership and the team’s achievements this month.”

About Dow

The Dow Chemical Company (Dow) combines science and technology knowledge to develop premier materials science solutions that are essential to human progress. Dow has one of the strongest and broadest toolkits in the industry, with robust technology, asset integration, scale and competitive capabilities that help it to address complex global issues. Dow’s market-driven, industry-leading portfolio of advanced materials, industrial intermediates, and plastics businesses deliver a broad range of differentiated technology-based products and solutions for customers in high-growth markets such as packaging, infrastructure, and consumer care. Dow is a subsidiary of DowDuPont Inc. (NYSE: DWDP), a holding company comprised of Dow and DuPont with the intent to form three strong, independent, publicly traded companies in agriculture, materials science and specialty sectors. More information can be found at www.dow.com.

®TM Trademark of The Dow Chemical Company (“Dow”) or an affiliated company of Dow


Contacts

Guillaume Artois
The Dow Chemical Company
+1 (989) 633 4573
GArtois@dow.com
or
Linda Lim
Dow Olympic & Sports Solutions
+65.9626.7662
LLim2@dow.com
or
Beth Crisafi
G&S Business Communications
+1.212.697.2600
bcrisafi@gscommunications.com

Japan Proton Therapy Market Research Report 2018 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Japan Proton Therapy Market Research Report 2018" report has been added to ResearchAndMarkets.com's offering.


This report examines the market dynamics, competitive landscape and discusses major trends. The research offers the most up-to-date industry data on the actual and potential market situation, and future outlook for proton therapy in Japan. The report includes historic data from 2012 to 2017 and forecasts until 2025.

Long-term Growth Projection:

  • Hitachi and Mitsubishi Electric Agree to Integrate Proton Therapy System Business
  • Japan is anticipated to be the most attractive market in the proton therapyindustry
  • The potential Japan proton therapy market is likely to reach more than USD 3 Billion by 2025
  • Mitsubishi Electric is a technology leader in the field of proton therapy in Japan.
  • Hitachi has the second highest share in the treatment rooms segment

Key Topics Covered:

1. Executive Summary

2. What is Proton Therapy?

3. Proton Therapy Current Applications

4. Proton Therapy Comparative Analysis

5. Market Size & Analysis: Japan Proton Therapy (2012 - 2025)

6. Market Opportunity Assessment: Japan Proton Therapy (2012 - 2025)

7. Key Market Drivers and Inhibitors of the Japan Proton Therapy Market

8. Japan Number of Treatment Rooms and Forecast (2012 - 2025)

9. Japan Proton Therapy Center (Installed Base) and Treatment Room Market Share: By Company

10. Japan Proton Therapy Center Infrastructure Analysis: Treatment Rooms & Proton Therapy Accelerator

11. Japan Number of Patients Treated at Proton Therapy Centers (2008 - 2016)

12. Japan Proton Therapy Reimbursement Scenario

13. Proton Therapy Center Component Analysis

14. Proton Therapy Clinical Trail Insight by Phase, Institute & Country

15. Proton Therapy Market - Major Deals

16. Key Companies Analysis

  • Hitachi
  • Ion Beam Application (IBA)
  • Mitsubishi Electric
  • Sumitomo Heavy Industries Ltd

For more information about this report visit https://www.researchandmarkets.com/research/dfpbx7/japan_proton?w=4


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Nuclear Medicine and Radiopharmacology

Entrust Datacard Earns Blue Shield Technology Innovation Award from the China International Association for Promotion of Science and Technology

Receiving China’s top security award cements Entrust Datacard as a leading security provider in the market


MINNEAPOLIS--(BUSINESS WIRE)--#cybersecurity--Entrust Datacard, a leading provider of trusted identity and secure transaction technology solutions, announces that the company has received the Blue Shield Technology Innovation Award for Security and Anti-Counterfeiting Technology for the Entrust Datacard Retransfer Card Printer series from the China International Association for Promotion of Science and Technology (CIAPST).

Established in 2010, the Blue Shield Technology Innovation Award for Security and Anti-Counterfeiting Technology was created to promote the innovation and application of security and anti-counterfeiting technology by companies around the world that conduct business in China, and is now viewed as the top award in the Chinese security industry.

Entrust Datacard received the Blue Shield Award for its Retransfer Card Printer series at the 12th Security Document Summit in Beijing, China. This on demand solution gives financial institutions, enterprises, universities and government programs the flexibility and features they need to issue identity, access and payment cards – right from their desktop. The printer provides long-lasting, high-definition images, while ensuring a deep level of security, durability and reliability.

“It’s an honor to be recognized as a leading security solution provider in the Chinese security industry and to have the Retransfer Printer series recognized as a top product in the market,” said Angus McDougall, regional vice president – APAC for Entrust Datacard. “We’re pleased to see that the Retransfer Printer series have not only provided a flexible and reliable identity platform, but has also redefined printing expectations for both our customers and the industry as a whole.”

This recognition is the result of Entrust Datacard’s 48 years of security expertise and over 20 years of providing trusted identity and transactions in China. In 2017, for example, Entrust Datacard reduced turnaround time from 30-45 days to the same day for a social security card issuance program across various provinces in China. This was achieved through an in region partner that implemented retransfer printers in a variety of provincial issuing locations.

“Entrust Datacard is dedicated to providing the most innovative printing solutions to our customers in China,” said Angus McDougall, regional vice president – APAC for Entrust Datacard. “This effort will continue as we enhance the capabilities of our retransfer printers and overall printing portfolio.”

Entrust Datacard offers a suite of desktop printers designed to provide card issuers with a unified solution for issuing identity credentials. These printers include the Entrust Datacard™ CR805™, CR825™ and CE875™ Instant Issuance Systems which makes up the Entrust Datacard ultimate identity platform.

For more information about the CR805 Retransfer Printer and the full suite of Entrust Datacard card printers, visit: https://www.entrustdatacard.com/products/categories/id-card-printers.

About Entrust Datacard Corporation

Consumers, citizens and employees increasingly expect anywhere-anytime experiences — whether they are making purchases, crossing borders, accessing e-gov services or logging onto corporate networks. Entrust Datacard offers the trusted identity and secure transaction technologies that make those experiences reliable and secure. Solutions range from the physical world of financial cards, passports and ID cards to the digital realm of authentication, certificates and secure communications. With more than 2,000 Entrust Datacard colleagues around the world, and a network of strong global partners, the company serves customers in 150 countries worldwide. For more information, visit www.entrustdatacard.com.


Contacts

Entrust Datacard
Heather Morris, +1 952-988-1745
Senior Manager, Global Communications
heather.morris@entrustdatacard.com

Optomec Partners with Tesscorn to Expand Additive Manufacturing Market in India

Tesscorn to Distribute Optomec LENS Systems for 3D Printed Metals and Aerosol Jet Systems for 3D Printed Electronics


ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Optomec, a leading global supplier of production grade additive manufacturing systems for 3D printed metals and 3D printed electronics, today announced it signed a distribution agreement with Tesscorn Nano Science, Inc. to expand sales of its solutions into India. Tesscorn is a leading distributor of integrated products, services, and support to the research and development community in India including Defense, Aerospace, Automotive, Military Forces and Universities.

Optomec Aerosol Jet printers provide high-resolution 3D printing capabilities required to manufacture smaller, lighter-weight, high-performance devices used in industries such as Aerospace, Defense, Consumer Electronics and the Internet of Things (IoT). Aerosol Jet technology is scalable for high volume production applications. The advanced printing technology uses patented aerodynamic focusing to precisely print electronic circuitry and functional components in dimensions ranging from as small as 10 microns to as large as several millimeters in a single pass. Click here for more information on the Aerosol Jet technology.

Optomec LENS printers use the energy from a high-power laser to build up structures one layer at a time, directly from powdered metals. The LENS process can completely build new metal parts or add material to existing metal components for repair and hybrid manufacturing applications. LENS technology is available in standalone system configurations or as a modular print engine for integration with CNC automation platforms. Click here for more information on LENS addition manufacturing technology.

Ramesh Athihalli, Director, Tesscorn Nano Science, Inc., stated:

We at Tesscorn, are excited to partner with Optomec to distribute 3D Printing/additive manufacturing technology in India. Our objective is to lead the digital revolution by empowering product designers and engineers to witness their innovations much faster than before and to empower India’s advanced manufacturing technology. Automation is spreading to every production line in India, and 3D printing is part of that trend. We at Tesscorn want to be an integral part of this revolution. The Aerosol Jet and LENS technology from Optomec are revolutionary technologies in this exciting field of 3D printing/additive manufacturing and our team at Tesscorn are dedicated towards adoption of these technologies to the huge bank of opportunities across various research and manufacturing industries in India.

“Over the past 25 years, Tesscorn has established itself as a leader in supplying advanced manufacturing technology for production and research use in India,” said Michael Kardos, Optomec Vice President of Worldwide Sales. “With their success in our target markets, we believe they can help expand the adoption of Optomec additive manufacturing solutions throughout India.”

About Tesscorn

Tesscorn Nano Science, Inc. was founded in 1993. The company has built its reputation as a leading supplier of top quality instrumentation for institutions in the Semiconductor, Solar and Nanotechnology manufacturing and research sectors. Over the years they have developed a network of suppliers, all leaders in their fields, providing unique manufacturing and research technologies across a broad spectrum of applications.

About Optomec

Optomec is a privately-held, rapidly growing supplier of production grade Additive Manufacturing systems. Optomec's patented Aerosol Jet systems for printed electronics and LENS 3D Printers for metal components are used by industry to reduce product cost and improve performance. Together, these unique printing solutions work with the broadest spectrum of functional materials, ranging from electronic inks to structural metals and even biological matter. Optomec has more than 300 marquee customers around the world, targeting production applications in the Electronics, Energy, Life Sciences and Aerospace industries.

LENS (Laser Engineered Net Shaping) is a registered trademark of Sandia National Laboratories. Aerosol Jet is a registered trademark of Optomec Inc.

Twitter- https://twitter.com/optomecinc
Facebook- www.facebook.com/optomec
LinkedIn- https://www.linkedin.com/company/optomec


Contacts

Optomec
Shayna Watson, 505-761-8250
swatson@optomec.com

Cognate Completes Management Buyout and Raises Growth Capital to Fund Commercial Cellular Therapy Manufacturing Expansion

BALTIMORE & MEMPHIS, Tenn.--(BUSINESS WIRE)--Cognate BioServices, a leading contract development and manufacturing organization (“CDMO”) in the global cellular therapies industry, announced today it has completed a management buyout (“MBO”) and raised capital from a group of global investment firms including Santa Monica, Calif.-based Tennenbaum Capital Partners, LLC (“TCP”), Medivate Partners and affiliates (“Medivate”) based in Seoul, South Korea and a sovereign wealth fund.


“As an early investor in Cognate, we are very excited to expand our partnership with the company,” said Dan Worrell, Managing Director of TCP. “For the past two decades, TCP’s healthcare strategy has focused on investing in companies that improve healthcare by lowering costs or facilitating improved patient access and outcomes. Cognate provides critical cost-effective support to small, medium, and large biotech companies on the forefront of personalized medicine. We are pleased to continue our participation in funding their growth and expansion.”

With a successful track record in manufacturing products for innovative therapeutic drugs in oncology and regenerative medicine (on behalf of its clients and partners), Cognate is one of the only CDMOs capable of handling the personalized products that are being approved by regulators today. The company recently opened up new manufacturing capacity to support products for both the E.U. and the U.S. in Memphis, Tennessee, and is well on its way to being able to support commercial scale production. The transaction includes significant growth capital to accelerate Cognate’s second phase of commercial expansion that began in 2015.

“This transaction is the culmination of years of planning and execution on the part of our highly collaborative and dedicated team with committed investors who came together to make this a reality,” according to J. Kelly Ganjei, CEO of Cognate BioServices, Inc. “We are excited to have completed the second phase of our growth strategy and look forward to further demonstrating our compelling and unique value proposition to the cell therapy market.”

The MBO and capital raise will accelerate Cognate’s commercial activities for clients and prospects, secure the company’s future as a leading CDMO in the emerging cellular therapies space and provide a clear path to commercialization.

“Our investment was driven by a combination of the tremendous opportunity in personalized cell therapy manufacturing and our confidence in the strong management team at Cognate,” said Medivate’s Managing Partner Roger Kang. “We are very excited to be a part of this syndicate and look forward to being part of their continued growth.”

About Cognate BioServices

Cognate BioServices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development and manufacture of cell-based products. The combination of highly experienced staff, successful track records and cGMP facilities makes Cognate one of the most qualified contract manufacturers of cell-based products in the world today.

About Tennenbaum Capital Partners, LLC

Tennenbaum Capital Partners, LLC ("TCP") is an alternative investment management firm with approximately $9 billion of committed capital focused on direct lending and special situations for middle-market companies. TCP manages funds and accounts on behalf of global institutional investors. Since its founding in 1999, TCP has invested approximately $19 billion in over 500 companies. TCP is headquartered in Los Angeles with additional offices in Atlanta, New York and San Francisco. For more information, please visit: www.tennenbaumcapital.com and www.tcpcapital.com.

About Medivate Partners

Medivate, is a private equity and venture capital firm that focuses investment in biotech/healthcare industry in Asia and North America. The firm is well positioned to capture surging healthcare investment opportunities between Asia and North America, and looks to arbitrage the unique cross border investment advantages. While closing its third fund, Medivate Partners quickly built a reputation for providing inner circle access to top caliber syndicates and successful life science deals in Asia and North America.


Contacts

For Cognate BioServices
Elasticity for Cognate BioServices
Aaron Perlut, 314-800-7218
aaron@goelastic.com
or
For Tennenbaum Capital Partners, LLC
Investors:
Tennenbaum Capital Partners, LLC
Katie McGlynn, 310-899-4948
or
Media:
Financial Profiles
Tricia Ross, 310-622-8226

Global Clinical Trial Management System Market Analysis & Trends 2015-2017 & Industry Forecast 2017-2027 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Clinical Trial Management System Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.


The Global Clinical Trial Management System Market is poised to grow strong during the forecast period 2017 to 2027. Some of the prominent trends that the market is witnessing include significant growth potential in emerging markets, growing R&D expenditure in pharmaceutical and biotechnology companies and technological advancements in CTMS offerings.

This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies for the existing players, new entrants and the future investors.

Scope of the Report

  • Based on type, market is segmented into enterprise CTMS and site CTMS.
  • By delivery mode, clinical trial management system market is categorized by Cloud-based (SaaS) CTMS, Licensed Enterprise (On Premise) CTMS and Web-based (Hosted) CTMS.
  • Depending on component, market is divided into hardware, services and software.
  • On the basis of application, market is classified by site management solutions, document management solutions, patient management solutions and data management solutions.
  • Contract research organizations, medical device companies, pharmaceutical & biopharmaceutical companies and other end users are the end users covered in this report.

Key Topics Covered:

1 Market Outline

2 Executive Summary

3 Market Overview

4 Clinical Trial Management System Market, By Type

5 Clinical Trial Management System Market, By Delivery Mode

6 Clinical Trial Management System Market, By Component

7 Clinical Trial Management System Market, By Application

8 Clinical Trial Management System Market, By End User

9 Clinical Trial Management System Market, By Geography

10 Key Player Activities

11 Leading Companies

  • Arisglobal
  • Bioclinica
  • Bio-Optronics, Inc.
  • Clinical Data
  • Datatrak
  • DSG
  • DZS Software Solutions
  • ERT
  • Forte Research Systems Inc.
  • Guger Technologies
  • IBM
  • Mastercontrol
  • Medidata Solutions
  • Mednet Solutions
  • Merge Healthcare Incorporated
  • Oracle Corporation
  • PAREXEL International Corporation
  • Veeva Systems

For more information about this report visit https://www.researchandmarkets.com/research/gs83xr/global_clinical?w=4.


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials

Global Dark Chocolate Market Analysis, Trends & Industry Forecast 2015-2018 & 2027 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Dark Chocolate Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.


The Global Dark Chocolate Market is poised to grow strong during the forecast period 2017 to 2027. Some of the prominent trends that the market is witnessing include increasing health benefits associated with cocoa-rich dark chocolates, rising demand for premium dark chocolates as gifts, players introducing more limited edition seasonal chocolates and burgeoning marketing initiatives.

This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies for the existing players, new entrants and the future investors.

Scope of the Report

  • Based on type, market is segmented by 70% cocoa dark chocolate, 75% cocoa dark chocolate, 80% cocoa dark chocolate and 90% cocoa dark chocolate.
  • By product, market is categorized into bitter chocolate, pure bitter chocolate and semi sweet chocolate.
  • On the basis of distribution channel, market is classified into online sales and offline sales.

Key Topics Covered:

1 Market Outline

2 Executive Summary

3 Market Overview

4 Dark Chocolate Market, By Type

5 Dark Chocolate Market, By Product

6 Dark Chocolate Market, By Distribution Channel

7 Dark Chocolate Market, By Geography

8 Key Player Activities

9 Leading Companies

  • Alfred Ritter
  • Amul
  • August Storck
  • Blommer Chocolate
  • Brookside Foods
  • Cmoi
  • Chocolate Frey
  • Crown Confectionery
  • Ezaki Glico
  • Ferrero Group
  • Hershey's
  • Mars
  • Mondelez International
  • Nestle

For more information about this report visit https://www.researchandmarkets.com/research/xqqmb7/global_dark?w=4.


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Chocolate and Cocoa Products

Global & US Gene Therapy Market Forecast to 2018-2020: Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global & US Gene Therapy Market Forecast to 2020" report has been added to ResearchAndMarkets.com's offering.


According to the report, most of the gene therapy researches are being focused on finding the treatment for cancer, followed by genetic diseases and neurological disorders, respectively. In this context, the gene therapy application chapter of the report provides a comprehensive overview of various diseases in which the gene therapy is used, along with the current and future market size of gene therapy for particular disease and its geographical break up.

The major part of the revenue of gene therapy market is generated from the research phase. Most of the gene therapy products are in research phases, only few products have been commercialized till date. The report also provides the sales of major marketed gene therapy products, and the list of the products in clinical/pre-clinical research along with their clinical phases.

North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market.

Key Topics Covered:

1. Research View

2. Research Methodology

3. Gene Therapy - An Introduction

4. Industry Overview

5. Clinical Trial Assessment & Pipeline Analysis

6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario

7. Marketed Gene Therapies

8. Gene Therapy Market

9. Gene Therapy Market by Application

10. Gene Therapy Market Size by Geography

11. Competitive Landscape

12. Key Players Analysis

  • Companies Mentioned
  • Advantagene Inc.
  • Bluebird Bio
  • Genethon
  • Human Stem Cells Institute
  • Oxford BioMedica Plc
  • Sanofi
  • Shanghai Sunway Biotech Co. Ltd.
  • Sibiono GeneTech Co. Ltd.
  • Spark Therapeutics, LLC
  • uniQure N.V.
  • Vical Inc.
  • ViroMed Co. Ltd. dba VM BioPharma

For more information about this report visit https://www.researchandmarkets.com/research/tkqxw5/global_and_us?w=4.


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics

Covalon Announces its Participation in Medical Japan 2018

  • Covalon to showcase its proprietary advanced wound and infection control products as part of the Ontario Government’s Life Sciences Trade Mission to Japan.
  • Medical Japan is the country’s largest trade show focusing on products, services and technologies for healthcare.


MISSISSAUGA, Ontario--(BUSINESS WIRE)--#lifesciencesmission--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it will be participating in the Ontario Government’s Life Sciences Trade Mission to Japan, which will include exhibiting at the Ontario Pavilion of Medical Japan 2018 at the International Exhibition Center (INTEX) in Osaka, Japan from February 21st to 23rd.

Covalon will feature its line of proprietary single-use infection control and advanced wound management products, which have been gaining acceptance in markets all over the world. Covalon’s ColActive® Plus, IV Clear, SurgiClear, and recently United States FDA cleared MediClear PreOp brands have strong clinical evidence to support their efficacy, and are often used to treat or prevent conditions that disproportionately impact the elderly, a sizeable portion of the Japanese population. Roughly 25 per cent of Japan's population is currently over the age of 65, compared to just 16.1 per cent in Canada. Between 2010 and 2060, the percentage of Japanese citizens over the age of 75 will more than double from 11 per cent to 27 per cent, according to the Japanese government.1

“Japan’s healthcare practitioners are open to innovative products to deal with conditions that affect the elderly,” said Brian Pedlar, Covalon’s Chief Executive Officer. “Our advanced products are designed specifically to address issues that negatively affect elderly patients, such as diabetic foot ulcers and medical adhesive skin injuries. Medical Japan 2018 is a great opportunity for Covalon to begin to enter the Japanese market in a meaningful way.”

In addition to the pavilion at Medical Japan 2018, the Ontario Government’s Life Sciences Trade Mission is planning several other events, including on-site visits and presentations at the Kansai-Ontario Life Sciences Seminar, as well as business-to-business meetings during the exhibition.

MEDICAL JAPAN, consisting of seven specialized shows, is Japan’s largest tradeshow, and covers all products, services, and technologies for healthcare, clinical testing, diagnostics, and medicine. To learn more about Covalon’s products, visit Covalon at the Ontario Pavilion 18-68 at Medical Japan 2018, INTEX Osaka, Japan during exhibit hours or email colactive@covalon.com

About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

1 Marlow, Iain. November 12, 2017. Japan’s Bold Steps. theglobeandmail.com


Contacts

Covalon Technologies Ltd.
Brian Pedlar, 905-568-8400 x 233
CEO
bpedlar@covalon.com
Toll free: 1-877-711-6055
www.covalon.com
Twitter: @covalon

North Korean ICBM Design Shows External Influence, Jane’s by IHS Markit Says

LONDON--(BUSINESS WIRE)--North Korea has made use of external knowledge, technology or hardware in its ballistic missile programme, according to a report from Jane’s by IHS Markit (Nasdaq: INFO), a world leader in critical information, analytics and solutions.

The report, which first appeared in Jane’s Intelligence Review, brings together two highly respected experts on North Korea’s ballistic missile programme, Markus Schiller and Nick Hansen*. It analyses the Hwaseong-15 (also known as ‘Hwasong-15’) intercontinental ballistic missile (ICBM) launched by North Korea in November 2017.

Writing for Jane’s, Schiller and Hansen assess that “it is highly likely that North Korea made use of foreign knowledge, technology or hardware in the development of the Hwaseong-15 ICBM.”

The November launch attracted international media attention, after North Korea’s state news agency claimed that the missile was “capable of striking the whole mainland of the United States.” It capped a year in which North Korea’s ballistic missile programme made a series of unprecedented advances. Most recently, on 8 February, North Korea displayed what appeared to be four Hwaseong-15 missiles during a military parade in Pyongyang.

Given the limited time and test resource available to North Korea, it is highly unlikely that North Korea could design, develop, engine test and integrate the components into … intercontinental missile systems without external assistance,” the report notes.

Moreover, it is likely that this knowledge, technology or hardware was derived from the Soviet-era ballistic missile programme. According to the report, “the design of the Hwaseong-15 missile is similar in some respects to the Soviet UR-100 family and there is a clear resemblance between the Hwaseong-15 first-stage engine and the Soviet RD-250 engine.”

However, based on the information available in open sources, Jane’s cannot assess with any confidence when this transfer took place. “The UR-100 family of missiles and the RD-250 engine have been in existence for decades,” said Neil Ashdown, deputy editor of Jane’s Intelligence Review.

North Korea could have acquired information about them from a range of sources, including some available online,” Ashdown said. “Even if North Korea did acquire hardware relating to these systems, we cannot say with any confidence where that would have come from, and more importantly when. That does not mean a transfer did not take place -- just that we cannot prove that based on the information we have.”

The report notes that the Hwaseong-15 had not been seen in open sources before it was first launched in November 2017, and that in key respects, it differs from previously observed North Korean missiles. This suggests that North Korea has pursued multiple lines of development in its ballistic missile programme.

Moreover, the successful integration of a higher-energy liquid propellant engine into the Hwaseong-15 with minimal observed testing suggests that North Korea could do the same with another missile. This raises the possibility that there may be further, as yet undisclosed, liquid propellant systems in development, which may emerge over the course of 2018.

*Markus Schiller is a space technology analyst and CEO of ST Analytics.
Nick Hansen is an imagery specialist and an affiliate at Stanford University.
Neil Ashdown is the deputy editor of Jane’s Intelligence Review.

About IHS Markit (www.ihsmarkit.com)

IHS Markit (Nasdaq: INFO) is a world leader in critical information, analytics and solutions for the major industries and markets that drive economies worldwide. The company delivers next-generation information, analytics and solutions to customers in business, finance and government, improving their operational efficiency and providing deep insights that lead to well-informed, confident decisions. IHS Markit has more than 50,000 business and government customers, including 80 percent of the Fortune Global 500 and the world’s leading financial institutions. Headquartered in London, IHS Markit is committed to sustainable, profitable growth.

About Jane’s Intelligence Review

Jane’s Intelligence Review is a security and intelligence publication produced by IHS Markit.

IHS Markit is a registered trademark of IHS Markit Ltd. and/or its affiliates. All other company and product names may be trademarks of their respective owners © 2018 IHS Markit Ltd. All rights reserved.


Contacts

IHS Markit
Joanna Vickers, +44 207 260 2234
joanna.vickers@ihsmarkit.com
or
Press Team, +1-303-305-8021
press@ihsmarkit.com

E Ink’s Partnership with Papercast Delivers Japan’s First Smart Signage Bus Stop

The Smart Displays Leverage E Ink’s ePaper Technology and Offer a Cost-Saving Digital Alternative to Conventional Paper Signage



BILLERICA, Mass.--(BUSINESS WIRE)--E Ink Holdings, "E Ink" (8069.TW), the leading innovator of electronic ink technology, and Papercast Ltd., a provider of solar powered passenger information display technology, today announced their partnership to deploy Japan’s first smart bus stop displays, piloting in Aizuwakamatsu city, 135 miles from Tokyo. The next generation smart bus stop leverages E Ink’s ePaper solution and low power wide area (LPWA) wireless technology to provide real-time information such as bus arrivals, timetables, route data, route transfers, planned and unplanned service changes.

Managed remotely by Papercast’s data management platform, the smart bus stop displays will replace traditional paper signage, reducing the high cost of manually updating information. Digitally connecting bus stops will also provide passengers with a more convenient way to access transportation information in real-time. In addition, the displays provide multi-language services for travelers, creating a better travel experience.

“By utilizing E Ink’s ePaper display solutions, we have developed a platform that is cost-effective, low-power and easy to use,” said Rado Skender, director of Business Development at Papercast, Ltd. “We anticipate that this partnership will enable widespread adoption in Japan and other countries as it improves the customer experience and encourages the use of public transportation among residents and out of town visitors.”

The inherent paper-like properties of E Ink technology make it ideal for bus signs as the display will be easily viewed under direct sunlight, and due to E Ink’s bistable technology, displays can hold an image without power since power is only required when the image or content is changing or being updated. This attribute allowed Papercast to create a solar-powered sign that alleviates the need for electrical wiring.

The project is administered by Aizu Riding Car Development, a consortium initiated by Michinori Holdings, operator of the Aizuwakamatsu bus service, Aizu Bus. The goal of the consortium is to improve service convenience and reduce ongoing costs by digitally connecting bus stops. In Japan, there are over 500,000 bus stops with 90 percent having no power source, so it was a pre-requisite that the display technology used is low-power and can be easily installed without connecting to the grid or using network cables.

“As cities become smart, E Ink will continue to play an integral part in the development of smart signage for transportation, retail and architecture,” said Dr. FY Gan, executive vice president of sales at E Ink Holdings. “E Ink’s technology allows integrators to leverage alternative power sources, such as solar, saving municipalities the cost of not only ongoing electric fees, but the cost of construction to run new power lines for installations, and the impact to citizens as the construction occurs. Our partnership with Papercast is another perfect example of how we’re enabling more convenient and cost-effective innovations that positively impact user experience and the environment.”

For more information on E Ink’s digital signage solutions visit, http://www.eink.com/signage.html

About E Ink Holdings

E Ink Holdings Inc. (8069.TWO), based on technology from MIT’s Media Lab, has transformed and defined the eReader market and is redefining the signage, architecture and design, mobile, wearable and retail markets with its ePaper technology, enabling a new multi-billion dollar market in less than 10 years. Its corporate philosophy aims to deliver revolutionary products, user experiences and environmental benefits through advanced technology development. This vision has led to its continuous investments in the field of ePaper displays as well as expanding the use of its technologies into a number of other markets and applications including smart packaging and fashion. Its Electrophoretic Display products make it the worldwide leader for ePaper. Its Fringe Field Switching (FFS) technologies are a standard for high-end LCD displays and have been licensed to all major liquid crystal display makers in the world. Listed in Taiwan's Taipei Exchange (TPEx) and the Luxembourg market, E Ink Holdings is now the world's largest supplier of ePaper displays. For more information please visit www.eink.com.

About Papercast

Papercast’s next generation bus stop passenger information solution uses self-sustainable standalone solar powered e-paper displays, with a comprehensive content management system developed exclusively for public transport needs. The platform enables transport providers to effortlessly keep passengers informed on real-time and advance service information at bus stops in a clear and user-friendly format. www.papercast.com


Contacts

E Ink
Lauren Ginsberg, +1-617-624-3254
lginsberg@racepointglobal.com
or
Papercast
Kerry Marchbank, +44 (0)7817 916654
kmarchbank@papercast.com

Global Walnut Market Analysis & Trends 2015-2017 – Industry Forecasts 2018-2027 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Walnut Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.


The Walnut Market is poised to grow strong during the forecast period 2017 to 2027. Some of the prominent trends that the market is witnessing include changing lifestyle habits and food preference, increasing awareness about health beneficial of walnuts and growing demand from cosmetic industry.

This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies for the existing players, new entrants and the future investors.

Scope of the Report

  • Based on nature, market is segmented into conventional and organic.
  • By product type, market is categorized into English or Persian walnut and black walnut.
  • On the basis of category, market is classified into shelled and in shell.
  • By form, market is categorized into processed and raw.
  • Processed are further classified into oil and powder.
  • On the basis of end use, market is classified into pharmaceuticals, personal care & cosmetics, household and food industry.
  • Food industries are further classified into bakery & confectionery, butter & spread, desserts, sauces & dressings and snacks.

Key Topics Covered:

1 Market Outline

2 Executive Summary

3 Market Overview

4 Walnut Market, By Nature

5 Walnut Market, By Product Type

6 Walnut Market, By Category

7 Walnut Market, By Form

8 Walnut Market, By End Use

9 Walnut Market, By Geography

10 Key Player Activities

11 Leading Companies

  • Agromillora Group
  • Alpine Pacific Nut
  • Andersen Shelling Inc
  • Borges India Private Limited
  • California Walnut Company
  • Crain Walnut Shelling Inc
  • Empire Nut Company, LLC
  • Gold River Orchards
  • Grower Direct Nut Co. Inc
  • Guerra Nut Shelling Company
  • Haleakala Walnut Shelling Inc
  • Kashmir Walnut Group
  • Mid Valley Nut
  • Morada Produce Company L.P.
  • Poindexter Nut Company
  • Royal Saffron company
  • Snyder's-Lance, Inc.
  • Webster Limited

For more information about this report visit https://www.researchandmarkets.com/research/g6fpz2/global_walnut?w=4.


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Nuts, Seeds and Dried Fruit

Global Public Transport Smart Card Market Report 2018: Analysis & Trends 2015-2027 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Public Transport Smart Card Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.


The Global Public Transport Smart Card Market is poised to grow strong during the forecast period 2017 to 2027. Some of the prominent trends that the market is witnessing include increasing urbanization in emerging countries, growing awareness about smart technologies and raising investments from governments.

This industry report analyzes the market estimates and forecasts of all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2015, 2016 revenue estimations are presented for 2017 and forecasts from 2018 till 2027.

The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies for the existing players, new entrants and the future investors.

Based on component, the market is categorized into memory card-based smart cards and micro controller based smart cards. On the basis of interface market is classified into contact less smart cards, contact smart cards and other interfaces. Based on mode of transport, the market is categorized into bus, train, light rail transit and other transportation modes.

Key Topics Covered:

1 Market Outline

2 Executive Summary

3 Market Overview

4 Public Transport Smart Card Market, By Component

5 Public Transport Smart Card Market, By Interface

6 Public Transport Smart Card Market, By Mode of Transport

7 Public Transport Smart Card Market, By Geography

8 Key Player Activities

9 Leading Companies

  • Advantech Co., Ltd.
  • American Express Company
  • Atos SE
  • Conduent Incorporated
  • CPI Card Group Inc.
  • Frequentis AG
  • Giesecke & Devrient GmbH
  • Infineon Technologies AG
  • Metro Infrasys Pvt. Ltd.
  • Moxa Inc.
  • NXP Semiconductors N.V.
  • Oberthur Technologies S.A.
  • OEM Technology Solutions
  • Texas Instruments, Inc.
  • ZTE Corporation

For more information about this report visit https://www.researchandmarkets.com/research/brtg2m/global_public?w=4


Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Public Transport , Smart Cards

Reliance Industries Limited to Acquire Stake in Eros International PLC

Announces Joint Partnership with Eros India to set-up a $150 million fund to co-produce and consolidate content

Jyoti Deshpande to head RIL’s media and entertainment business as President of the Chairman’s Office

MUMBAI, India--(BUSINESS WIRE)--Reliance Industries Limited (“RIL”) and Eros International PLC (“Eros”) announced today that RIL, through a subsidiary, has agreed to subscribe to a 5% equity stake in NYSE listed Eros at a price of $15.00 per share, which represents an 18% premium to last closing price. The transaction is subject to customary regulatory and other approvals.


Furthermore, RIL and Eros International Media Limited (“Eros India”) announced that they have agreed to partner in India to jointly produce and consolidate content from across India. The parties will equally invest up to approximately $150 million to produce and acquire Indian films and digital originals across all languages.

In addition, it was announced that Ms. Jyoti Deshpande, Group CEO and MD of Eros will be stepping down from her Executive role after more than 17 years in Eros and move on to head the Media and Entertainment business at RIL as President of the Chairman’s Office. Ms. Deshpande will start her role at RIL from April 2018, but will continue to remain as a Non-Executive Director on the Board of Eros. Mr. Kishore Lulla will resume his position of Group Chairman and CEO of Eros.

In her new role at RIL, Ms. Deshpande will lead the company’s initiatives in Media and Entertainment to organically build and grow businesses around the content ecosystem such as Broadcasting, Films, Sports, Music, Digital, Gaming, Animation etc., as well as integrate RIL’s existing media investments such as Viacom and Balaji Telefilms with a view to build, scale and consolidate the fragmented $20 billion Indian M&E sector.

Mukesh Ambani, Chairman & Managing Director, RIL commented, “We are pleased to join hands with Eros, as it will bring further synergies into our plans, making for a win-win partnership. We are delighted to welcome Ms. Jyoti Deshpande into the Reliance family and believe that she will not only give wings to our plans but also play a pivotal role in transforming the sector.”

Commenting on the development Mr. Kishore Lulla said, “I am very pleased that Eros is partnering with RIL in its entertainment journey with several synergies across technology, content and digital with Eros Now. We look forward to collaborating and growing as we continue to make new strides on the digital and content forefronts. I am confident that together, we can make a meaningful difference. Jyoti Deshpande has been an invaluable part of the incredible Eros growth journey and I am confident that she will make a positive impact on the industry in her new role at RIL. I wish her the very best of luck.”

Ms. Jyoti Deshpande commented, “Having worked and associated with Eros group since 1998, it has been an integral part of my professional career and I extend my heartfelt thanks to Kishore Lulla and the Eros family for the opportunity to build an amazing company together. I am delighted that RIL has strategically aligned with Eros, so the association continues. My new assignment at RIL will allow me to push boundaries, set new standards of excellence, assemble a world-class young leadership team and adopt a collaborative approach to architect and execute this ambition in true RIL tradition. I am genuinely honored and humbled to have been granted this opportunity but more than anything I cannot wait to roll up my sleeves.”

About RIL

RIL is India’s largest private sector company, with a consolidated turnover of INR 330,180 crore (USD 50.9 billion), cash profit of INR 42,800 crore (USD 6.6 billion), and net profit of INR 29,901 crore (USD 4.6 billion) for the year ended March 31, 2017.

RIL is the first private sector company from India to feature in Fortune’s Global 500 list of ‘World’s Largest Corporations’ – currently ranking 203rd in terms of revenues, and 110th in terms of profits. The company stands 106th in the ‘Forbes Global 2000’ rankings for 2017 – the top-most among Indian companies. It ranks 10th in LinkedIn’s ‘Top Companies Where India Wants to Work Now’ (2017). RIL’s activities span hydrocarbon exploration and production, petroleum refining and marketing, petrochemicals, retail and 4G digital services.

About Eros International Plc

Eros International Plc (NYSE: EROS) is a leading global company in the Indian film entertainment industry that acquires, co-produces and distributes Indian films across all available formats such as cinema, television and digital new media. Eros International Plc became the first Indian media company to list on the New York Stock Exchange. Eros International has experience of over three decades in establishing a global platform for Indian cinema. The Company has an extensive and growing movie library comprising of over 3,000 films, which include Hindi, Tamil, and other regional language films. The company also owns the rapidly growing OTT platform Eros Now. For further information please visit: www.erosplc.com.

About Jyoti Deshpande

Ms. Jyoti Deshpande has over 25 years of experience in media and entertainment across advertising, media consulting, television and film. She has been part of the leadership team of Eros International Plc since 2001 and as Group CEO & MD she has spearheaded Eros’s growth as a global leader in Indian filmed entertainment. Prior to joining Eros in 2001, Ms Deshpande has worked for 7 years in the field of advertising, media consulting and television with companies such as J Walter Thompson India, Mindshare, Zee Television and B4U Television. Ms. Deshpande has a Bachelor’s Degree in Commerce and Economics from Mumbai University and a Master’s Degree in Business Administration (MBA) from SPJIMR, Mumbai University.

Ms. Deshpande was featured in the prestigious Fortune India magazine’s 50 Most Powerful Women in Business (2017/2015) which celebrates the journeys and triumphs of women who not only impact their organizations but are also thought leaders in their industry. Ms. Deshpande was also featured in the list of Top 50 Most Powerful Women in Business by Business Today (2015). She was also recently awarded as one of the Women of the Decade for Innovation and Leadership by Women Economic Forum.


Contacts

Eros International Plc
Mark Carbeck, +44 207 258 9909
Chief Corporate and Strategy Officer
mark.carbeck@erosintl.com
or
Media:
Sloane & Company
Erica Bartsch, +1 212 446 1875
ebartsch@sloanepr.com